Key facts
- NV Therapeutics’s last known valuation is $9.5M (Mar 2025).
- It has raised $7.5M across 1 recorded rounds; the latest was Seed Round ($3.0M) in Sep 2024.
- Notable investors include 4BIO Capital.
- NV Therapeutics has filed 1 Form D with the SEC, most recently Mar 2025 ($3.0M sold to 1 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for NV Therapeutics
Funding rounds
1 roundsAbout NV Therapeutics
Developer of gene writing technology designed for advanced gene therapy development purposes. The company's technology focuses on non viral genome engineering with an emphasis on safer operation, scalability, and reduced manufacturing complexity, applies controlled writing to support development and implementation across therapeutic programs, and is built to run using existing laboratory infrastructure rather than specialized viral systems, enabling researchers and therapy developers to accelerate creation of accessible treatments with improved production feasibility and broader clinical reach.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2024
- Employees
- 3
- Website
- nvtx.bio/
- Ownership
- Privately Held (backing)
NV Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NV Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NV Therapeutics in its N-PORT filings yet. We sweep new filings monthly.